BR112016029492A2 - método para tratamento de linfoma não hodgkin - Google Patents
método para tratamento de linfoma não hodgkinInfo
- Publication number
- BR112016029492A2 BR112016029492A2 BR112016029492A BR112016029492A BR112016029492A2 BR 112016029492 A2 BR112016029492 A2 BR 112016029492A2 BR 112016029492 A BR112016029492 A BR 112016029492A BR 112016029492 A BR112016029492 A BR 112016029492A BR 112016029492 A2 BR112016029492 A2 BR 112016029492A2
- Authority
- BR
- Brazil
- Prior art keywords
- administering
- subject
- hodgkin
- lymphoma
- treatment
- Prior art date
Links
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 title abstract 2
- 101150090105 Ezh2 gene Proteins 0.000 abstract 3
- 239000003112 inhibitor Substances 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- NSQSAUGJQHDYNO-UHFFFAOYSA-N n-[(4,6-dimethyl-2-oxo-1h-pyridin-3-yl)methyl]-3-[ethyl(oxan-4-yl)amino]-2-methyl-5-[4-(morpholin-4-ylmethyl)phenyl]benzamide Chemical compound C=1C(C=2C=CC(CN3CCOCC3)=CC=2)=CC(C(=O)NCC=2C(NC(C)=CC=2C)=O)=C(C)C=1N(CC)C1CCOCC1 NSQSAUGJQHDYNO-UHFFFAOYSA-N 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229950004774 tazemetostat Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/65—One oxygen atom attached in position 3 or 5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
a presente invenção se relaciona com métodos de tratamento de câncer por administração de um inibidor de ezh2 ou uma sua composição farmacêutica ao sujeito com sua necessidade. as presentes reivindicações definem métodos para tratamento de subtipos específicos de linfoma não hodgkin compreendendo a administração a um sujeito de inibidores de ezh2. inibidores de ezh2 preferenciais incluem tazemetostat (epz6438 e7438) e outros compostos. quantidades e regimes de dosagem são também definidos.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462013522P | 2014-06-17 | 2014-06-17 | |
| US201462036265P | 2014-08-12 | 2014-08-12 | |
| PCT/US2015/036310 WO2015195848A1 (en) | 2014-06-17 | 2015-06-17 | Ezh2 inhibitors for treating lymphoma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112016029492A2 true BR112016029492A2 (pt) | 2017-10-17 |
Family
ID=54936086
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112016029492A BR112016029492A2 (pt) | 2014-06-17 | 2015-06-17 | método para tratamento de linfoma não hodgkin |
Country Status (21)
| Country | Link |
|---|---|
| US (5) | US10166238B2 (pt) |
| EP (2) | EP3157527B1 (pt) |
| JP (1) | JP6779793B2 (pt) |
| KR (2) | KR102497728B1 (pt) |
| CN (2) | CN113289022A (pt) |
| AU (3) | AU2015277139A1 (pt) |
| BR (1) | BR112016029492A2 (pt) |
| CA (1) | CA2952074C (pt) |
| DK (1) | DK3157527T3 (pt) |
| EA (1) | EA038337B1 (pt) |
| ES (1) | ES2948442T3 (pt) |
| FI (1) | FI3157527T3 (pt) |
| HU (1) | HUE062158T2 (pt) |
| IL (3) | IL309539A (pt) |
| LT (1) | LT3157527T (pt) |
| MX (2) | MX2021007651A (pt) |
| PL (1) | PL3157527T3 (pt) |
| PT (1) | PT3157527T (pt) |
| SG (2) | SG11201610273VA (pt) |
| SI (1) | SI3157527T1 (pt) |
| WO (1) | WO2015195848A1 (pt) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2841142C (en) | 2010-06-23 | 2020-12-15 | Ryan D. Morin | Biomarkers for non-hodgkin lymphomas and uses thereof |
| EA201691079A1 (ru) | 2013-12-06 | 2017-03-31 | Эпизим, Инк. | Комбинированная терапия для лечения онкологического заболевания |
| CN113289022A (zh) * | 2014-06-17 | 2021-08-24 | Epizyme股份有限公司 | 用于治疗淋巴瘤的ezh2抑制剂 |
| CN106794177A (zh) | 2014-10-16 | 2017-05-31 | Epizyme股份有限公司 | 治疗癌症的方法 |
| KR102338802B1 (ko) * | 2014-11-17 | 2021-12-14 | 에피자임, 인코포레이티드 | 암을 치료하기 위한 방법 |
| AR102767A1 (es) | 2014-12-05 | 2017-03-22 | Lilly Co Eli | Inhibidores de ezh2 |
| MX2017013142A (es) | 2015-04-20 | 2019-03-28 | Epizyme Inc | Terapia combinada para tratar cáncer. |
| EP3307713A4 (en) | 2015-06-10 | 2019-01-23 | Epizyme, Inc. | EZH2 INHIBITOR FOR THE TREATMENT OF LYMPHOMA |
| SG10201909199PA (en) | 2015-08-24 | 2019-11-28 | Epizyme Inc | Method for treating cancer |
| TW201718598A (zh) | 2015-08-27 | 2017-06-01 | 美國禮來大藥廠 | Ｅｚｈ２抑制劑 |
| EP3407978A4 (en) | 2016-01-29 | 2020-01-15 | Epizyme Inc | COMBINATION THERAPY FOR TREATING CANCER |
| EP3464643A4 (en) | 2016-06-01 | 2020-04-01 | Epizyme Inc | USE OF EZH2 INHIBITORS FOR THE TREATMENT OF CANCER |
| JP2019521988A (ja) * | 2016-06-17 | 2019-08-08 | エピザイム，インコーポレイティド | 癌を処置するためのｅｚｈ２阻害剤 |
| JP2020506905A (ja) * | 2017-01-20 | 2020-03-05 | コンステレーション・ファーマシューティカルズ・インコーポレイテッドＣｏｎｓｔｅｌｌａｔｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． | （ｒ）−ｎ−（（４−メトキシ−６−メチル−２−オキソ−１，２−ジヒドロピリジン−３−イル）メチル）−２−メチル−１−（１−（１−（２，２，２−トリフルオロエチル）ピペリジン−４−イル）エチル）−１ｈ−インドール−３−カルボキサミド固体分散液 |
| US11642346B2 (en) | 2017-03-31 | 2023-05-09 | Epizyme, Inc. | Combination therapy for treating cancer |
| EP3630080A4 (en) | 2017-06-02 | 2021-03-10 | Epizyme, Inc. | USE OF EZH2 INHIBITORS FOR THE TREATMENT OF CANCER |
| WO2019014191A1 (en) * | 2017-07-10 | 2019-01-17 | Constellation Pharmaceuticals, Inc. | GENE EXPRESSION INDUCED BY EZH2 INHIBITOR |
| CN111093660A (zh) | 2017-09-05 | 2020-05-01 | Epizyme股份有限公司 | 用于治疗癌症的组合疗法 |
| CN110960525A (zh) * | 2019-11-26 | 2020-04-07 | 济南大学 | 新型eed-ezh2相互作用抑制剂的确定和评价 |
| CN110950834A (zh) * | 2019-11-26 | 2020-04-03 | 济南大学 | 新型eed-ezh2相互作用小分子抑制剂的确定和评价 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US7229774B2 (en) | 2001-08-02 | 2007-06-12 | Regents Of The University Of Michigan | Expression profile of prostate cancer |
| US8895245B2 (en) * | 2010-09-10 | 2014-11-25 | Epizyme, Inc. | Inhibitors of human EZH2 and methods of use thereof |
| US9175331B2 (en) | 2010-09-10 | 2015-11-03 | Epizyme, Inc. | Inhibitors of human EZH2, and methods of use thereof |
| AU2012223448B2 (en) | 2011-02-28 | 2017-03-16 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
| TW201733984A (zh) | 2011-04-13 | 2017-10-01 | 雅酶股份有限公司 | 經取代之苯化合物 |
| JO3438B1 (ar) | 2011-04-13 | 2019-10-20 | Epizyme Inc | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس |
| BR112014007603A2 (pt) | 2011-09-30 | 2017-06-13 | Glaxosmithkline Llc | métodos de tratamento do câncer |
| ES2718900T3 (es) * | 2012-03-12 | 2019-07-05 | Epizyme Inc | Inhibidores de EZH2 humana y métodos de uso de los mismos |
| EP2836491B1 (en) | 2012-04-13 | 2016-12-07 | Epizyme, Inc. | Salt form of a human histone methyltransferase ezh2 inhibitor |
| AU2013245661B2 (en) | 2012-04-13 | 2017-11-23 | Epizyme, Inc. | Combination therapy for treating cancer |
| US9562041B2 (en) | 2012-05-16 | 2017-02-07 | Glaxosmithkline Llc | Enhancer of zeste homolog 2 inhibitors |
| WO2014062732A1 (en) | 2012-10-15 | 2014-04-24 | Epizyme, Inc. | Substituted benzene compounds |
| KR20190105669A (ko) | 2012-10-15 | 2019-09-17 | 에피자임, 인코포레이티드 | 암을 치료하는 방법 |
| JP6584952B2 (ja) * | 2012-11-01 | 2019-10-02 | インフィニティー ファーマシューティカルズ， インコーポレイテッド | Ｐｉ３キナーゼアイソフォームモジュレーターを用いる癌の治療 |
| US20140120083A1 (en) | 2012-11-01 | 2014-05-01 | Infinity Pharmaceuticals, Inc. | Treatment of cancers using pi3 kinase isoform modulators |
| US20150283142A1 (en) | 2013-03-15 | 2015-10-08 | Infinity Pharmaceuticals, Inc. | Treatment of cancers using pi3 kinase isoform modulators |
| EP2934531A4 (en) | 2012-12-19 | 2016-06-15 | Glaxosmithkline Llc | COMBINATION |
| WO2014100665A1 (en) | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | 1,4-pyridone bicyclic heteroaryl compounds |
| US20150344427A1 (en) | 2012-12-21 | 2015-12-03 | Epizyme, Inc. | 1,4-pyridone compounds |
| US20160031907A1 (en) | 2013-03-15 | 2016-02-04 | Epizyme, Inc. | Substituted Benzene Compounds |
| EP2970306A4 (en) | 2013-03-15 | 2016-08-03 | Epizyme Inc | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS CONDENSED IN 6.5 |
| DK3003309T3 (da) | 2013-05-30 | 2020-12-14 | Infinity Pharmaceuticals Inc | Behandling af cancer med PI3-kinase-isoform modulatorer |
| WO2015010078A2 (en) | 2013-07-19 | 2015-01-22 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
| WO2015010049A1 (en) | 2013-07-19 | 2015-01-22 | Epizyme, Inc. | Substituted benzene compounds |
| ES2705573T3 (es) | 2013-10-09 | 2019-03-26 | Hoffmann La Roche | Procedimientos y composiciones para detectar mutaciones en el gen EZH2 humano |
| PT3057962T (pt) | 2013-10-16 | 2023-11-07 | Epizyme Inc | Forma de sal cloridrato para inibição de ezh2 |
| AU2014337121A1 (en) | 2013-10-18 | 2016-04-14 | Epizyme, Inc. | Method of treating cancer |
| EA201691079A1 (ru) | 2013-12-06 | 2017-03-31 | Эпизим, Инк. | Комбинированная терапия для лечения онкологического заболевания |
| CN113289022A (zh) | 2014-06-17 | 2021-08-24 | Epizyme股份有限公司 | 用于治疗淋巴瘤的ezh2抑制剂 |
| CN107249593A (zh) | 2014-11-06 | 2017-10-13 | 达纳-法伯癌症研究所股份有限公司 | 调节染色质结构的组合物用于移植物抗宿主疾病(gvhd)的用途 |
| KR102338802B1 (ko) | 2014-11-17 | 2021-12-14 | 에피자임, 인코포레이티드 | 암을 치료하기 위한 방법 |
| JP6544507B2 (ja) | 2015-02-09 | 2019-07-17 | 日本精機株式会社 | ヘッドアップディスプレイ装置 |
| EP3307713A4 (en) | 2015-06-10 | 2019-01-23 | Epizyme, Inc. | EZH2 INHIBITOR FOR THE TREATMENT OF LYMPHOMA |
| KR20170095656A (ko) | 2016-02-15 | 2017-08-23 | 동부대우전자 주식회사 | 방열구조를 갖는 세탁기 |
-
2015
- 2015-06-17 CN CN202110532717.0A patent/CN113289022A/zh active Pending
- 2015-06-17 KR KR1020177000760A patent/KR102497728B1/ko active IP Right Grant
- 2015-06-17 SG SG11201610273VA patent/SG11201610273VA/en unknown
- 2015-06-17 EA EA201692285A patent/EA038337B1/ru unknown
- 2015-06-17 MX MX2021007651A patent/MX2021007651A/es unknown
- 2015-06-17 EP EP15809540.6A patent/EP3157527B1/en active Active
- 2015-06-17 ES ES15809540T patent/ES2948442T3/es active Active
- 2015-06-17 IL IL309539A patent/IL309539A/en unknown
- 2015-06-17 CN CN201580036258.XA patent/CN106999498B/zh active Active
- 2015-06-17 US US15/319,535 patent/US10166238B2/en active Active
- 2015-06-17 AU AU2015277139A patent/AU2015277139A1/en not_active Abandoned
- 2015-06-17 FI FIEP15809540.6T patent/FI3157527T3/fi active
- 2015-06-17 KR KR1020237004113A patent/KR20230031963A/ko not_active Application Discontinuation
- 2015-06-17 JP JP2016573564A patent/JP6779793B2/ja active Active
- 2015-06-17 MX MX2016016744A patent/MX2016016744A/es unknown
- 2015-06-17 PL PL15809540.6T patent/PL3157527T3/pl unknown
- 2015-06-17 EP EP23174369.1A patent/EP4252851A3/en active Pending
- 2015-06-17 BR BR112016029492A patent/BR112016029492A2/pt not_active Application Discontinuation
- 2015-06-17 WO PCT/US2015/036310 patent/WO2015195848A1/en active Application Filing
- 2015-06-17 CA CA2952074A patent/CA2952074C/en active Active
- 2015-06-17 HU HUE15809540A patent/HUE062158T2/hu unknown
- 2015-06-17 LT LTEPPCT/US2015/036310T patent/LT3157527T/lt unknown
- 2015-06-17 PT PT158095406T patent/PT3157527T/pt unknown
- 2015-06-17 SG SG10201811128RA patent/SG10201811128RA/en unknown
- 2015-06-17 DK DK15809540.6T patent/DK3157527T3/da active
- 2015-06-17 IL IL285201A patent/IL285201B2/en unknown
- 2015-06-17 SI SI201531951T patent/SI3157527T1/sl unknown
-
2016
- 2016-12-07 IL IL249438A patent/IL249438A0/en unknown
-
2018
- 2018-11-06 US US16/181,747 patent/US20190175604A1/en not_active Abandoned
-
2019
- 2019-06-27 US US16/454,835 patent/US20200022987A1/en not_active Abandoned
-
2020
- 2020-03-04 US US16/808,513 patent/US11642347B2/en active Active
- 2020-09-28 AU AU2020244382A patent/AU2020244382B2/en active Active
-
2022
- 2022-11-03 AU AU2022263523A patent/AU2022263523A1/en active Pending
-
2023
- 2023-03-23 US US18/188,716 patent/US20240058348A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112016029492A2 (pt) | método para tratamento de linfoma não hodgkin | |
| PH12018500642A1 (en) | Anti-garp antibody | |
| MX2021006734A (es) | Metodo para tratar el cancer. | |
| MX2020010535A (es) | Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide. | |
| EA201792529A1 (ru) | Ингибиторы тирозинкиназы | |
| MX2018005019A (es) | Derivado benzofurano, su metodo de preparacion, y sus usos en medicinas. | |
| EA201791018A1 (ru) | Производные 6-амино-7-бицикло-7-деазапурина в качестве ингибиторов протеинкиназы | |
| EA201890567A1 (ru) | Способ лечения рака | |
| EA201790170A1 (ru) | Терапевтические соединения-ингибиторы | |
| MX2016015434A (es) | Combinaciones farmaceuticas para tratar cancer. | |
| BR112020015915A8 (pt) | Usos de um anticorpo anti-pd-1 e um anticorpo anti-ctla4 ou fragmentos de ligação ao antígeno dos mesmos, bem como kit para tratamento de um paciente com câncer | |
| EA201592238A1 (ru) | Ингибиторы протеинкиназы pi3k, в частности ингибиторы pi3k дельта и/или гамма | |
| MX2017004618A (es) | Inhibidores de la biosintesis de sulfato de heparano para el tratamiento de enfermedades. | |
| EA201690159A1 (ru) | Способы и композиции для лечения рака | |
| EA201790576A1 (ru) | Спироциклические ингибиторы катепсина с | |
| MX2019001011A (es) | Compuestos farmaceuticos. | |
| EA202191513A1 (ru) | Снижение вязкости фармацевтических составов | |
| BR112017014793A2 (pt) | regime de dosagem para antagonistas de madcam | |
| MX370270B (es) | Inhibidores de glucosilceramida sintasa para el tratamiento de enfermedades. | |
| BR112017026535A2 (pt) | composto de fórmula estrutural i, enantiômero isolado, composição farmacêutica, método para inibir atividade do transportador de monocarboxilato mct4, método para inibir seletivamente atividade do transportador de monocarboxilato mct4, método para tratar um distúrbio mediado por transportador de monocarboxilato mct4 e uso de um composto | |
| EA201692481A1 (ru) | Комбинация, содержащая глюкокортикоид и edo-s101 | |
| EA201690039A1 (ru) | Ингибиторы rorc2 и способы их применения | |
| EA201792341A1 (ru) | Производные пиразола, пригодные в качестве ингибиторов белка, активирующего 5-липоксигеназу (flap) | |
| BR112018003836A2 (pt) | combinações de inibidor de btk para tratar mieloma múltiplo | |
| EA201791933A1 (ru) | Ингибирование активности olig2 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B07G | Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette] |
Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021 |
|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] |